Related Experiment Video

Updated: Jun 6, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Bilateral papilledema on sunitinib therapy for advanced renal cell carcinoma

Jaclyn Yoong1, Geoffrey Chong, K Hamilton

  • 1Ballarat Base Hospital, Drummond Street North, Ballarat, VIC 3350, Australia. jackieyoong@hotmail.com

Medical Oncology (Northwood, London, England)
|November 9, 2010
PubMed

Insights

A 59-year-old man with advanced kidney cancer experienced bilateral papilledema during sunitinib treatment. This is the first reported case linking sunitinib, a multi-targeted tyrosine kinase inhibitor, to this vision-related side effect.

Area of Science:

  • Oncology
  • Nephrology
  • Ophthalmology

Background:

  • Advanced renal cell carcinoma (RCC) treatment often involves targeted therapies.
  • Multi-targeted tyrosine kinase inhibitors (TKIs) are a key class of drugs used in RCC therapy.
  • Understanding the side effect profile of TKIs is crucial for patient management.

Observation:

  • A 59-year-old male patient with advanced RCC was undergoing treatment with sunitinib.
  • The patient presented with bilateral papilledema, a swelling of the optic disc.
  • Papilledema is a condition that can affect vision and requires medical attention.

Findings:

  • This case represents the first documented instance of bilateral papilledema associated with sunitinib therapy.
  • While another TKI, imatinib, has been linked to papilledema, this specific association with sunitinib is novel.
  • The findings highlight a potential, previously unreported adverse event of sunitinib.

Implications:

  • Clinicians should be aware of the potential for sunitinib to cause papilledema in renal cell carcinoma patients.
  • Ophthalmological monitoring may be warranted for patients on sunitinib, especially if visual symptoms arise.
  • Further research is needed to elucidate the mechanism and incidence of sunitinib-induced papilledema.

More Related Videos

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas07:43

Endoscopic Endonasal Trans-sphenoidal Approach: Minimally Invasive Surgery for Pituitary Adenomas

Published on: January 17, 2018

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Nephrotic Syndrome III : Nursing Management01:24

Nephrotic Syndrome III : Nursing Management

Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...